Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 01 November 2011
This month's theme is economics and regulatory strategy. Although it is still common for many regulatory professionals to be concerned only with the pure scientific/regulatory side of their work, as the profession has evolved over the years, the ambit of advice they provide has expanded-and with it, their need for knowledge of the entire product lifecycle, from the glimmer in an inventor's eye, through research, trials, approval and even marketing. Many of these stages require an eye to the economics of product development, launch and even postmarket events.
To that end, we have gathered several lead articles this month to give you insight into various aspects of the dollar side of the regulatory business. Regular contributor Philipp Novales-Li gives us an excellent introduction to the whole topic of pharmacoeconmics, reminding us that the link between products and health outcomes can and usually should be quantified. Although no one wants to put a price on human health, reality demands that we measure the effectiveness of products and treatments.
Ray Huml gives us a detailed focus on "patient-centric services," the design of programs to increase effectiveness and lower costs. By taking this perspective, we are able to judge the differences between treatments and preventative steps (including inducing behavioral changes). The article discusses some sophisticated applications of IT technology to healthcare decision making.
Since costs are our focus, we also have an introduction to device clinical trial cost management by Jeffrey Zigler. Device IDE costs have been significantly affected by recent government initiatives and other factors. Zigler gives us the lowdown on the impact of Medicare contracting changes on IDE planning and makes some suggestions for controlling these complications and costs.
Finally, my colleague Thomas Wong and I revisit and debunk a recurring theme about the economics of drug marketing in Canada. Many American regulatory professionals of my acquaintance continue to assume that, because practitioner services are covered by governmental programs in Canada, drugs are similarly "free." This is not the case, and what drugs will be covered by provincial governments in Canada-and to what degree-can have a critical impact on decisions as to whether a particular drug treatment will be made available there.
The most important economic factor to remember is that Regulatory Focus is free to you-a great member benefit of RAPS. Enjoy, with no opportunity cost or other economic consideration!
Tags: economics, In Focus, regulatory